Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.
Margaret K. Callahan
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose
Emily Chan
Consultant or Advisory Role - Amgen; Castle Biosciences
Research Funding - Bristol-Myers Squibb
Michael Morse
No relevant relationships to disclose
Rathi Narayana Pillai
No relevant relationships to disclose
Petri Bono
Honoraria - Bristol-Myers Squibb
Dirk Jaeger
No relevant relationships to disclose
T.R. Jeffry Evans
Other Remuneration - Bristol-Myers Squibb
Ian Chau
Consultant or Advisory Role - Bristol-Myers Squibb; Gilead Sciences; Lilly; Merck Serono; Novartis; Roche; Sanofi
Honoraria - Lilly; Sanofi ; Taiho Pharmaceutical
Research Funding - Merck Serono; Novartis; Roche; Sanofi
Emiliano Calvo
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Dung T. Le
No relevant relationships to disclose
Patrick Alexander Ott
No relevant relationships to disclose
Matthew Hiram Taylor
No relevant relationships to disclose
Padmanee Sharma
Consultant or Advisory Role - Bristol-Myers Squibb; Dendreon; Jounce Therapeutics; MedImmune
Stock Ownership - Jounce Therapeutics
Research Funding - Bristol-Myers Squibb
Scott Joseph Antonia
Consultant or Advisory Role - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Research Funding - MedImmune
Brian Sharkey
Employment or Leadership Position - Bristol-Myers Squibb
Olaf Christensen
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Asim Amin
Consultant or Advisory Role - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb